Z-LEHD-fmk Options
The key end level was the protection and tolerability of sifalimumab. Treatment method-emergent adverse situations (AEs) and significant AEs (SAEs) and their severity, outcome, and any romantic relationship to the research medication have been recorded from the investigator all through the review. AEs were being regarded prone to be connected with